WARNING:
JavaScript is turned OFF. None of the links on this concept map will
work until it is reactivated.
If you need help turning JavaScript On, click here.
This Concept Map, created with IHMC CmapTools, has information related to: 20131126_Zortress_cmap, loss to follow-up is defined by last day of contact was prior to study Day 316, biopsy grade can be IIB, loss to follow-up do(es) not include biopsy proven acute rejection (bpar), mouth ulcerations is an adverse event, patients are denoted as loss to follow-up, blood and lymphatic system disorders are an adverse event, biopsy grade can be IB, M-TOR inhibitors can cause pneumonitis, metabolic syndrome is linked to patient loss, graft loss can be assessed at 6 months, infections and infestations are an adverse event, M-TOR inhibitors are associated with proteinuria, cardiovascular risk is associated with hyperlipidemia, death can be assessed at 12 months, death is assessed at study completion, loss to follow-up do(es) not include death, gastrointestinal events include diarrhea, general disorders and administration site conditions are an adverse event, gastrointestinal events include nausea, graft loss can be assessed at 12 months